Literature DB >> 24363464

IMPROVED SYNTHESIS OF 10-(2-ALKYLAMINO-2-OXOETHYL)-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID DERIVATIVES BEARING ACID-SENSITIVE LINKERS.

Bhumasamudram Jagadish1, Tarik J Ozumerzifon1, Sue A Roberts1, Gabriel B Hall1, Eugene A Mash1, Natarajan Raghunand2.   

Abstract

Alkylation of the n class="Chemical">hydrobromide salts of 1,4,7-tris(methoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane and 1,4,7-tris(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane with appropriate α-bromoacetamides, followed by hydrolysis, provides convenient access to 10-(2-alkylamino-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid derivatives that contain acid-sensitive functional groups. The utility of the method is demonstrated by improved syntheses of two known DOTA monoamides bearing acid-sensitive ω-tritylthio alkyl chains in much higher yields based on cyclen as the starting material.

Entities:  

Keywords:  Cyclen; DO3A monoamide; DOTA monoamide; medical imaging; synthesis

Year:  2014        PMID: 24363464      PMCID: PMC3866964          DOI: 10.1080/00397911.2013.813547

Source DB:  PubMed          Journal:  Synth Commun        ISSN: 0039-7911            Impact factor:   2.007


  28 in total

1.  Multimodal image-guided enzyme/prodrug cancer therapy.

Authors:  Cong Li; Paul T Winnard; Tomoyo Takagi; Dmitri Artemov; Zaver M Bhujwalla
Journal:  J Am Chem Soc       Date:  2006-11-29       Impact factor: 15.419

2.  Carboxymethyl-substituted bifunctional chelators: preparation of aryl isothiocyanate derivatives of 3-(carboxymethyl)-3-azapentanedioic acid, 3,12-bis(carboxymethyl)-6,9-dioxa-3,12-diazatetradecanedioic++ + acid, and 1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid for use as protein labels.

Authors:  S J Kline; D A Betebenner; D K Johnson
Journal:  Bioconjug Chem       Date:  1991 Jan-Feb       Impact factor: 4.774

3.  Bifunctional ligands based on the DOTA-monoamide cage.

Authors:  Alessandro Barge; Lorenzo Tei; Dharita Upadhyaya; Franco Fedeli; Lorena Beltrami; Rachele Stefanìa; Silvio Aime; Giancarlo Cravotto
Journal:  Org Biomol Chem       Date:  2008-02-22       Impact factor: 3.876

Review 4.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

5.  Synthesis and physicochemical characterization of new squalenoyl amphiphilic gadolinium complexes as nanoparticle contrast agents.

Authors:  Mohammad Othman; Didier Desmaële; Patrick Couvreur; Luce Vander Elst; Sophie Laurent; Robert N Muller; Claudie Bourgaux; Estelle Morvan; Thierry Pouget; Sinda Lepêtre-Mouelhi; Philippe Durand; Ruxandra Gref
Journal:  Org Biomol Chem       Date:  2011-04-12       Impact factor: 3.876

6.  Dual-isotope lymphoscintigraphy using albumin nanocolloid differentially labeled with 111In and 99mTc.

Authors:  J Charlotte Fowler; Chandra K Solanki; Robert W Barber; James R Ballinger; A Michael Peters
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

Review 7.  The synthesis and application of polyamino polycarboxylic bifunctional chelating agents.

Authors:  Luciano Lattuada; Alessandro Barge; Giancarlo Cravotto; Giovanni Battista Giovenzana; Lorenzo Tei
Journal:  Chem Soc Rev       Date:  2011-03-08       Impact factor: 54.564

Review 8.  The synthesis and chelation chemistry of DOTA-peptide conjugates.

Authors:  Luis M De León-Rodríguez; Zoltan Kovacs
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

Review 9.  Gallium-68 PET: a new frontier in receptor cancer imaging.

Authors:  A Al-Nahhas; Z Win; T Szyszko; A Singh; C Nanni; S Fanti; D Rubello
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

10.  Controlled preparation of a heterometallic lanthanide complex containing different lanthanides in symmetrical binding pockets.

Authors:  Louise S Natrajan; Aaron Joseph L Villaraza; Alan M Kenwright; Stephen Faulkner
Journal:  Chem Commun (Camb)       Date:  2009-08-20       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.